TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01789411

Intervention type: OTHER
Intervention: Drawing blood samples
Description: Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure

Intervention type: DEVICE
Intervention: Coronary intravascular ultrasound imaging
Description: Coronary intravascular ultrasound imaging of a non-culprit coronary artery.

Intervention type: DEVICE
Intervention: Coronary near-infrared spectroscopy
Description: Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
Study: NCT05800197

Intervention type: DRUG
Intervention: Tamoxifen 20mg
Description: Selective estrogen receptor modulator

Intervention type: DRUG
Intervention: Tamoxifen 20mg
Description: Selective estrogen receptor modulator

Intervention type: DRUG
Intervention: Anastrozole 1mg
Description: Aromatase Inhibitor

Intervention type: DRUG
Intervention: Anastrozole 1mg
Description: Aromatase Inhibitor

Intervention type: DRUG
Intervention: Letrozole 2.5mg
Description: Aromatase Inhibitor

Intervention type: DRUG
Intervention: Letrozole 2.5mg
Description: Aromatase Inhibitor

Intervention type: DRUG
Intervention: Goserelin
Description: Gonadotropin Releasing Hormone (GnRH) agonist

Intervention type: DRUG
Intervention: Triptorelin
Description: Gonadotropin Releasing Hormone (GnRH) agonist
Study: NCT03317223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420/Clarithromycin/Amoxicillin
Description: CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-12420/Clarithromycin/Amoxicillin
Description: CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
Study: NCT00185510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Aceponate (Advantan, BAY86-4862)
Description: In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 days a week Vehicle (Advabase)
Study: NCT01380301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine and antimony
Description: Short course (half of each drug) administered simultaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miltefosine alone
Description: short course (half)
Study: NCT02746913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urodynamics
Description: Urodynamics is performed with the Aquarius XT Laborie system and a fluoroscopic images are obtained with a GE OCE 9800 c-arm fluoroscopy unit. Urodynamic testing will be performed in a seated position with a pessary from the ambulatory pessary trial in place. Post residual void will be measured at the start of the urodynamics.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urodynamics
Description: Urodynamics is performed with the Aquarius XT Laborie system and a fluoroscopic images are obtained with a GE OCE 9800 c-arm fluoroscopy unit. Urodynamic testing will be performed in a seated position with a pessary from the ambulatory pessary trial in place. Post residual void will be measured at the start of the urodynamics.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pessary
Description: A pessary is a silicone disc that is used in to support the uterus and vagina of women with vaginal prolapse. During this study, the pessary that will be used is a ring with support. This is a disc shape with a membrane stretched across the center. It is a device used in standard practice and is safe to keep in place for up to 3 months at a time. The subjects will be fit with a pessary asked to wear the pessary for 3 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pessary
Description: A pessary is a silicone disc that is used in to support the uterus and vagina of women with vaginal prolapse. During this study, the pessary that will be used is a ring with support. This is a disc shape with a membrane stretched across the center. It is a device used in standard practice and is safe to keep in place for up to 3 months at a time. The subjects will be fit with a pessary asked to wear the pessary for 3 days.
Study: NCT02039661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Spray
Description: These patients received 2 puff lidocaine spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02823964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
Study: NCT02481401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Individual Intervention Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer-To-Peer Program Intervention
Study: NCT01645878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hands on
Description: in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hands off
Description: In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: routin breast feeding education
Study: NCT03391544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: V4c toric ICL implantation surgery
Description: The size and power of the V4c toric ICL were determined following the manufacturer's guidelines using a modified vertex formula. Emmetropia was the target refraction following surgery in all cases. Before surgery, three centration points were marked using the slit lamp while the patient, in sitting position, fixated on the center of the slit-lamp beam, which was narrowed as much as possible.
Study: NCT04703374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation I)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation I)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation I)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation I)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation I)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation I)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation II)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation II)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation II)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation II)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation II)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382(formulation II)
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026
Description: 1 tablet administered under fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026
Description: 1 tablet administered under fasting condition for 7days
Study: NCT01345981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: dosage 20 mg and 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: dosage 20 mg and 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: dosage 20 mg and 40 mg
Study: NCT04028427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values-plus-goals intervention
Description: The VGI is a four-week intervention, adapted from an existing online value-affirmation and goals intervention (Kingston \& Ellett, 2014) and an existing 'Living Well with Physical Health Conditions' programme handbook. Participants are first introduced to the concept of values as understood in Acceptance and Commitment Therapy. They are then asked to complete a card-sort task, which involves organising ten life domains according to their perceived level of importance. Participants will be asked to choose one values that is the most important and meaningful to them and to write for up to 10 minutes about it, thinking about why it is meaningful to them. Following this, participants will be given information on how to set value-based 'SMART' goals and asked to choose one to focus on over the next month. Participants will be sent a reminder e-mail every week over the 4 weeks, asking them to review their progress towards the SMART goal they set themselves.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: The MBI is a four-week intervention, where participants are introduced to the concept of mindfulness and acceptance as understood in ACT (Hayes et al., 1999). They will be asked to complete a 10-minute health-focused mindfulness meditation exercise by listening to a recording of a script focusing on cultivating mindful awareness of internal experiences, particularly in relation to diabetes, and practising making room for any difficult internal experiences. This will be followed by some prompts to promote reflections related to their diabetes following the exercise. They will be asked to practise this exercise 3-4 times a week over a four-week period. As a manipulation check, participants will be sent a reminder e-mail every week over the four weeks to record how many times they practised the exercise over the past week.
Study: NCT01065376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the timing cabergoline administration
Description: received 0.5 mg oral cabergoline per day for 8 days on the day of hCG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the timing cabergoline administration
Description: received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
Study: NCT02683655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg qd p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 750mg qd p.o.
Study: NCT03538977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: A re-sterilizable stainless steel bucket with an upper diameter of 30 cm, a depth of 32 cm, with water at a temperature between 37 and 38º Celsius will be used. The amount of water used will be sufficient to keep the baby submerged up to shoulder height. The baby will be immersed in the heated water of the bucket and will be suspended by occipital support performed by the physiotherapist, who alternates lateral-lateral and anteroposterior movements with only static suspension. The therapy will last from eight to ten minutes and will be discontinued if there is agitation, cyanosis, worsening respiratory distress or major evacuation. If the baby is using any type of ventilatory support or oxygen therapy, the same will be maintained during the procedure of hydrotherapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy consists of manipulations of Thoracoabdominal Rebalancing, a registered technique which uses simultaneous passive stretching of inspiratory muscles and stimulation of the diaphragm. The manipulation used to improve the dynamic diaphragm included the thoracic-abdominal and lower abdominal support maneuvers. Back repositioning was used to minimize posteriorization of the ribs and costal kyphosis due to thoracic distortion.
Study: NCT02327338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermacare heat wraps
Description: off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermacare heat wraps
Description: off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: thermacare heat wraps
Description: off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 1200 mg ibuprofen administered 400mg at 4 hour intervals

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ibuprofen
Description: 1200 mg ibuprofen administered 400mg at 4 hour intervals
Study: NCT01603745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoely
Description: 1 pill every day
Study: NCT03579914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous Placebo
Description: Patients receive intravenous Placebo (saline) injection
Study: NCT01603745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: 1 pill every day
Study: NCT01383629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling
Description: Preoperative counselling
Study: NCT04737395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: upper extremity training program (Meditouch,MSQUARE)
Description: 40 hours of therapy with the Hand Tutor (MediTouch) device and a wearable vest (EkssoUE, Ekso Bionics) for arm rehabilitation
Study: NCT03579914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Injectable Product
Description: Patients receive intravenous Metoprolol injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Romote Ischemic Conditioning (RIC)
Description: Patients receive RIC treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Metoprolol & RIC
Description: Patients receive Metoprolol \& RIC treatment
Study: NCT02233920

Intervention type: DRUG
Intervention: Ventilat® - metered dose inhaler
Study: NCT02406079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tracheotomy
Description: Tracheotomy is one of most performed surgical procedures to assure airway by making a hole in front of the trachea in ICU.
Study: NCT02062073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abametapir Lotion 0.74% w/w

Intervention type: OTHER
Group type: OTHER
Intervention: 0.1% sodium lauryl sulfate

Intervention type: OTHER
Group type: OTHER
Intervention: saline 0.9%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Study: NCT02901119

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Patients, maintaining their regular usual diet, are submitted to a protein supplementation, during 15 days. They recieve 20g packages of whey protein or casein, to take twice a day: 20g in the morning and 20g at night.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Patients, maintaining their regular usual diet, are submitted to a protein supplementation, during 15 days. They recieve 20g packages of whey protein or casein, to take twice a day: 20g in the morning and 20g at night.
Study: NCT00542906

Intervention type: OTHER
Group type: OTHER
Intervention: localization
Description: localization of the several types of somatosensory stimuli
Study: NCT02057029

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BCI Assay Results
Description: The nature of the intervention is to utilize the BCI results in the decision making process for ER-positive breast cancer patients and their physicians.
Study: NCT03330262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BALCAP prosthesis
Description: The noninvasive BALCAP prosthesis offers uses six degrees-of-freedom (6-DOF) sensing to detect postural imbalance and actuate low-amplitude vibrotactile cues directly to the head to provide the wearer with feedback concerning head tilt in the pitch and roll plane.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BALCAP prosthesis
Description: The noninvasive BALCAP prosthesis offers uses six degrees-of-freedom (6-DOF) sensing to detect postural imbalance and actuate low-amplitude vibrotactile cues directly to the head to provide the wearer with feedback concerning head tilt in the pitch and roll plane.
Study: NCT00355576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine
Description: 10 g BID for either study arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine
Description: 10 g BID for either study arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm
Study: NCT02343445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-1037
Description: P-1037 is a novel ENaC inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-1037
Description: P-1037 is a novel ENaC inhibitor

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hypertonic Saline
Description: 4.2% saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: 4.2% saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.17% saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.17% saline solution
Study: NCT01585662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided pancreatic pseudocyst drainage
Description: EUS-guided pancreatic pseudocyst drainage by one 8 French naso-pancreatic tube or 2-3 two pig tails- stents.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided pancreatic pseudocyst drainage
Description: EUS-guided pancreatic pseudocyst drainage by one 8 French naso-pancreatic tube or 2-3 two pig tails- stents.
Study: NCT00191282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin isophane suspension (NPH)
Description: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \>8.0%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin isophane suspension
Description: Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin 30/70
Description: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \>8.0%.
Study: NCT02689869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research \& Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA 101
Description: Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
Study: NCT02357706

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP A (ResMed AirSense AutoSet)
Description: Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP A (ResMed AirSense AutoSet)
Description: Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP B (Apex iCH Auto)
Description: Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP B (Apex iCH Auto)
Description: Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
Study: NCT02234596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.